Bibliography
- Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294(20):2581-6
- AstraZeneca Discontinues Development of GALIDA TM (tesaglitazar). AstraZeneca. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20060504--AstraZeneca-Discontinues-Development-of-GALIDA-TM-te [Last accessed 24 July 2014]
- Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771(8):1065-81
- Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8(5):399-416
- Matschinsky FM, Zelent B, Doliba NM, et al. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Handb Exp Pharmacol 2011(203):357-401; Review
- Ohyama S, Takano H, Iino T, et al. A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. Eur J Pharmacol 2010;640(1-3):250-6
- Bonadonna RC, Heise T, Arbet-Engels C, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010;95(11):5028-36
- Verspohl EJ. Novel pharmacological approaches to the treatment of type 2 diabetes. Pharmacol Rev 2012;64(2):188-237
- Gude D. Red carpeting the newer antidiabetics. J Pharmacol Pharmacother 2012;3(2):127-31
- Sarabu R, Bizzarro FT, Corbett WL, et al. Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients. J Med Chem 2012;55(16):7021-36
- Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011;34(12):2560-6
- Development activities. Takeda. Available from: http://www.takeda.com/research/files/pipeline_20140205_en.pdf [Last accessed 24 July 2014]
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-705; Review
- Inagaki N, Onouchi H, Sano H, et al. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2(2):125-32
- Takeda information. Takeda. Available from: https://www.takeda.com/investor-information/files/qr2013_full_d_01_en.pdf [Last accessed 24 July 2014]
- Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 2011;31(12):839-51
- Schwartz SL, Akinlade B, Klasen S, et al. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011;13(12):1219-27
- Veltkamp SA, van Dijk J, Collins C, et al. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther 2012;34(8):1761-71
- Zhang W, Krauwinkel WJ, Keirns J, et al. The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. Clin Drug Investig 2013;33(7):489-96
- Annual report 2013. Astellas. Available from: https://www.astellas.com/en/ir/library/pdf/astellas_ar2013_e_all_web.pdf [Last accessed 24 July 2014]
- Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421(6921):384-8
- Pavlov VA, Ochani M, Gallowitsch-Puerta M, et al. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci USA 2006;103(13):5219-23
- Bencherif M, Lippiello PM, Lucas R, Marrero MB. Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. Cell Mol Life Sci 2011;68(6):931-49
- Marrero MB, Lucas R, Salet C, et al. An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J Pharmacol Exp Ther 2010;332(1):173-80
- Targacept discontinues two clinical trials, reports success with a third. Craver R, Available from: http://www.journalnow.com/business/article_6fda73b9-c328-5762-af1d-5d711156beec.html?mode=jqm [Last accessed 6 August 2014]
- Bénardeau A, Benz J, Binggeli A, et al. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg Med Chem Lett 2009;19(9):2468-73
- Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54(8):2460-70
- Sanwald-Ducray P, Liogier D’ardhuy X, Jamois C, Banken L. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. Clin Pharmacol Ther 2010;88(2):197-203
- Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374(9684):126-35
- Nicholls SJ, Lincoff AM, Henry RR, et al. Aleglitazar, a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, produces a shift towards less atherogenic LDL profile in patients with type 2 diabetes (Abstract). Eur Heart J 2010;31:1020
- Lincoff AM, Tardif JC, Schwartz GG, AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 2014;311(15):1515-25
- Roche halts investigation of aleglitazar following regular safety review of phase III trial. Roche. Available from: http://www.roche.com/media/media_releases/med-cor-2013-07-10.htm [Last accessed 24 July 2014]
- Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003;422(6928):173-6
- Negoro N, Sasaki S, Mikami S, et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 2010;1(6):290-4
- Tsujihata Y, Ito R, Suzuki M, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 2011;339(1):228-37
- Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 2012;52(7):1007-16
- Leifke E, Naik H, Wu J, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 2012;92(1):29-39
- Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012;379(9824):1403-11
- Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 2013;36(2):245-50
- Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009;5(10):749-57
- Pfizer pipeline. Pfizer. Available from: http://www.pfizer.com/sites/default/files/product-pipeline/BT_February%2028,%202014%20Pipeline%20Update_28Feb14.pdf [Last accessed 24 July 2014]
- Pfizer pipeline. Pfizer. Available from: http://www.pfizer.com/sites/default/files/product-pipeline/pipeline_2013_0509.pdf [Last accessed 24 July 2014]
- Annual report. Piramal Enterprises Ltd. Available from: http://piramal.com/sites/default/files/PEL-Annual-Report-FY2013.pdf [Last accessed 24 July 2014]
- Orena S, Maurer TS, She L, et al. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol 2013;4:115
- Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med 1999;107:2B:34S-42S; Review
- Hellweg R, Hartung HD. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990;26(2):258-67
- Hellweg R, Raivich G, Hartung HD, et al. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 1994;130(1):24-30
- Fujinami A, Ohta K, Obayashi H, et al. Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: relationship to glucose metabolism and biomarkers of insulin resistance. Clin Biochem 2008;41(10-11):812-17
- Krabbe KS, Nielsen AR, Krogh-Madsen R, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007;50(2):431-8
- Rojas-Rivera J, Ortiz A, Egido J. Antioxidants in kidney diseases: the impact of bardoxolone methyl. Int J Nephrol 2012;2012:321714
- Ahmad R, Raina D, Meyer C, et al. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 2006;281(47):35764-9
- Lisk C, McCord J, Bose S, et al. Nrf2 activation: a potential strategy for the prevention of acute mountain sickness. Free Radic Biol Med 2013;63:264-73
- Aminzadeh MA, Reisman SA, Vaziri ND, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica 2014;44(6):570-8
- Pergola PE, Raskin P, Toto RD, BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365(4):327-36
- de Zeeuw D, Akizawa T, Audhya P, BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369(26):2492-503
- Chin MP, Reisman SA, Bakris GL, et al. Mechanisms contributing to. adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol 2014;39(6):499-508
- Kyowa Hakko Kirin announces the development status of bardoxolone methyl (RTA 402) in patients with chronic kidney disease and type 2 diabetes in Japan. Kyowa Hakko Kirin. Available from: http://www.kyowa-kirin.com/news_releases/2013/e20131111_01.html [Last accessed 24 July 2014]
- Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000;97(14):7667-9
- Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45(4):522-30
- Chen S, Iglesias-de la Cruz MC, Jim B, et al. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003;300(1):16-22
- Clinical development pipeline. Eli Lilly. Available from: http://www.lilly.com/SiteCollectionDocuments/Pipeline/Clinical%20Development%20Pipeline/8.html [Last accessed 24 July 2014]
- Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25(2):e140-50
- Morgan S, Grootendorst P, Lexchin J, et al. The cost of drug development: a systematic review. Health Policy 2011;100(1):4-17
- The cost of diabetes. The American Diabetes Association. Available from: http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html [Last accessed 7 September 2014]